Supplementary Methods S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Authors:
- Daniel MorgenszternDMDaniel Morgensztern
- Neal ReadyNRNeal Ready
- Melissa L. JohnsonMJMelissa L. Johnson
- Afshin DowlatiADAfshin Dowlati
- Noura ChoudhuryNCNoura Choudhury
- David P. CarboneDCDavid P. Carbone
- Eric SchaeferESEric Schaefer
- Susanne M. ArnoldSASusanne M. Arnold
- Sonam PuriSPSonam Puri
- Zofia PiotrowskaZPZofia Piotrowska
- Aparna HegdeAHAparna Hegde
- Anne C. ChiangACAnne C. Chiang
Open Access
- 15 November 2024
- other
- Published by American Association for Cancer Research (AACR)
Abstract
Definition of dose-limiting toxicities and methods for patient-derived xenograft studiesKeywords
This publication has 1 reference indexed in Scilit:
- ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer TumorsMolecular Cancer Therapeutics, 2022